Analyze.
Reset.
Revolutionize.

Revolo Biotherapeutics, formerly Immune Regulation
About
If you’re looking for a typical biotechnology company, you’ve come to the wrong place.
We are a revolutionary biotherapeutics company and our mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission
How?
By developing therapies that achieve superior long-term disease remission from less frequent chronic dosing and without suppression of the immune system. A goal that others haven’t been able to reach.
Why?
Existing therapies for autoimmune and allergic diseases require frequent chronic dosing, provide only short-term disease remission in a limited number of patients and suppress the immune system, ultimately putting patients at risk of developing serious infections and life-threatening side effects.
Product Development Landscape
Product Development Landscape
Our two platform drug candidates, ‘1805 and ‘1104, reset the immune system after only a single administration in an unmatched way. They have demonstrated unique efficacy and safety in preclinical and human studies without immune suppression. Given our disease-agnostic approach, we are uniquely positioned as Revolutionaries in the development of drugs for various autoimmune and allergic diseases.

Leadership
Industry veterans | Immunology and allergic disease experts | dedicated revolutionizers
Our Krewe

Jonathan Rigby, mba
Group Chief Executive Officer

Perry Calias, ph.d.
Chief Operating Officer

Jones W Bryan, ph.d.
Chief Business Officer

Dr. Roly Foulkes
Chief Scientific Officer

Jeff Myers, m.d., ph.d.
Chief Medical Officer

Dr. Clare Burgess
Chief Development Officer

Nancy Vinh
VP of Clinical Operations

Marylyn Rigby
VP of Marketing & Investor Relations
Board of Directors
Peter Greenleaf
Chairman
Jonathan Rigby, mba
Group Chief Executive Officer
Dr. Isaac Cheng, m.d.
Non-Executive Director
Michael Albisser
Non-Executive Director
news
Latest News
September 8, 2020 | Press Release
Immune Regulation Ltd receives notice of allowance for new U.S. patent for its novel protein with anti-inflammatory properties
March 27, 2020 | Press Release
Immune Regulation Ltd appoints Jonathan Rigby as Chief Executive Officer
Contact Us
We are always looking to revolutionize treatment paradigms and happy to chat with you about yours or ours. Interested? We are!